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Niemann–Pick type C (NPC) disease is characterized at the cellular level by the intracellular accumulation of free cholesterol. We have
previously identified a similar phenotype in cystic fibrosis (CF) cell models that results in the activation of the small GTPase RhoA. The
hypothesis of this study was that NPC cells would also exhibit an increase in small GTPase activation. An examination of the active, GTP-bound
form of GTPases revealed a basal increase in the content of the active-form Ras and RhoA small GTPases in NPC fibroblasts compared to wt
controls. To assess whether this increase in GTP-bound Ras and RhoA manifests a functional outcome, the expression of the proliferation control
proteins p21/waf1 and cyclin D were examined. Consistent with increased GTPase signaling, p21/waf1 expression is reduced and cyclin D
expression is elevated in NPC fibroblasts. Interestingly, cell growth rate is not altered in NPC fibroblasts compared to wt cells. However, NPC
sensitivity to statin treatment is reversed by addition of the isoprenoid geranylgeranyl pyrophosphate (GGPP), a modifier of RhoA. It is concluded
that Ras and RhoA basal activation is elevated in NPC fibroblasts and has an impact on cell survival pathways.
© 2007 Elsevier B.V. All rights reserved.Keywords: Niemann–Pick type C; RhoA; Ras; Cyclin D; p21/waf11. Introduction
At the cellular level, Niemann–Pick type C (NPC) disease is
characterized by improper intracellular cholesterol accumula-
tion in the late endosomal/lysosomal compartments [1].
Previously, we have demonstrated that NPC fibroblasts share
similar cell signaling protein expression profiles with model
cells of cystic fibrosis (CF) including expression alterations in
the transforming growth factor-β1 (TGF-β1) signaling protein
SMAD3, signal transducer and activator of transcription-1
(STAT1), and the small GTPase RhoA [2]. Included in the
signaling alterations associated with NPC fibroblasts was an
inability to induce the expression of the inducible nitric oxide
synthase (NOS2) [2]. Reduced NOS2 expression is consistent
with an increase in the activation of the small GTPase RhoA, a
known negative regulator of NOS2 expression [3–5]. The hy-⁎ Corresponding author. Tel.: +1 216 368 0831; fax: +1 216 368 4223.
E-mail address: tjk12@cwru.edu (T.J. Kelley).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.03.008pothesis of this study is that small GTPase activation is
increased in NPC cells and influences cellular functions.
Relatively little is currently known about the cell signaling
consequences of losingNPC1 function, but there are suggestions
of altered GTPase signaling. Garver et al. have demonstrated that
protein kinase C (PKC) isozymes and pp60-src exhibit increased
expression in liver homogenates in Npc1−/− mice [6]. This
manuscript provides evidence of the involvement of caveolin-1
containing fractions in the NPC cell signaling regulation, and
Gingras et al. have shown that RhoA GTPase is localized in
caveolin-1 containing membrane domains in endothelial cells
[7]. In addition, Taggart et al. report that the caveolin-1
scaffolding domain is essential in co-localizing PKC and
RhoA in smooth muscle [8]. Taken together, these data suggest
a possible role for RhoA in NPC-related signaling alterations.
Similarly, indications of reduced peroxisome proliferator-
activated receptor-γ (PPARγ) function in NPC cells have been
reported [9]. RhoA has been demonstrated to be an effective
inhibitor of PPARγ signaling suggesting a possible source for
altered PPAR regulation [10]. Although these cell-signaling
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for increased GTPase activity, they are consistent with an
alteration in the GTPase pathway and warrant a further
examination of GTPase activation.
The goal of this manuscript is to examine small GTPase
signaling and to determine if NPC cells exhibit alterations
consistent with elevated GTPase activation. A prediction of
elevated GTPase signaling, particularly RhoA and Ras, is a
skewing of cell-signaling regulation to favor proliferation. For
example, a study by Liberto et al. demonstrated that elevated Ras
and RhoA signaling in breast cancer cells resulted in reduced
p21/waf1 and elevated cyclin D protein expression [11]. These
signaling parameters were examined in NPC fibroblasts to test
whether they would exhibit these changes consistent with
elevated GTPase activation. The signaling relationship to be
examined in this study is shown in Fig. 1.
Results from this study demonstrate that both RhoA and Ras
GTPases exhibit increased basal activation in NPC fibroblasts
compared to control cells. Consistent with the work by Liberto et
al., the expression of p21/waf1 is reduced in NPC cells and the
expression of cyclin D is elevated. It is concluded from this study
that both RhoA and Ras GTPases are basally more active in NPC
cells compared to controls and that this activation impacts the
expression of proliferation control signaling proteins. Increased
activation of small GTPases, particularly RhoA, is likely the
source of the observed sensitivity of NPC cells to apoptosis
mediated by inhibition of HMG-CoA reductase [12,13].
2. Methods
2.1. Cell culture
Niemann–Pick fibroblasts (NPC) (GM03123A) containing two missense
mutations in the NPC1 gene were obtained from Coriell Cell Repository
(Camden, NJ). Control human fibroblasts (CRL-2076) were obtained from
American Type Culture Collection (ATCC, Manassas, VA). The cells were
grown at 37 °C in 95% O2–5% CO2 on Falcon 10 cm diameter tissue cultureFig. 1. Schematic diagram of proposed signaling relationships inNPC fibroblasts.dishes in MEM Eagle with 2 mM L-glutamine containing 15% fetal bovine
serum (FBS) and 1u/ml penicillin/streptomycin.
2.2. GTPase activity assays
Rho and Ras activity were assayed using kits obtained from Upstate
Biotechnology, Lake Placid, NY) according to manufacturer’s instructions.
Details of the RhoA assay are as follows: Rho activity was determined using a
Rho Activation Assay Kit (Upstate Biotechnology, Lake Placid, NY). This assay
was used previously to determine RhoA activity in CF samples [14,15]. Cells
were placed in 300 μl 1× Mg2+ lysis buffer (25 mM HEPES, pH 7.5, 150 mM
NaCl, 1% Igepal CA-630, 10 mMMgCl2, 1 mM EDTA, and 2% glycerol) on ice
and homogenized for 60 s. Homogenates were centrifuged at 14,000×g for 5 min
at 4 °C to clear cellular debris and protein concentration was determined. To
assay for GTP-γ-S-dependent activation of RhoA, samples were either left
untreated or loaded with GTP-γ-S. 5 μl of 10 mM GTP-γ-S was added to each
respective aliquot and incubated for 30 min at 30 °C. The reaction was
terminated by placing samples on ice and adding 32 μl 1 M MgCl2. Active
(GTP/GTP-γ-S-bound) Rho was isolated by pull-down assay: 50 μl (30 μg) of
Rhotekin Rho Binding Domain (RBD) agarose bead slurry (50 mM Tris, pH 7.5,
0.5% Triton X-100, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 0.1 mM
PMSF 1 μg/ml each of aprotinin and leupeptin) was added to each 500 μl aliquot
and incubated for 45 min at 4 °C with gentle agitation. The Rhotekin-RBD
agarose bead-Rho complex was pulled-down by brief centrifugation (10 s,
14,000×g, 4 °C). The supernatant was removed and the beads washed three
times. The beads were resuspended in 40 μl Laemmli buffer containing 5% 2-
mercaptoethanol and western-blot analysis performed using Anti-RhoA
antibody from Santa Cruz biotechnologies (Santa Cruz, CA). (1:1000 dilution)
incubated overnight at 4 °C. The effect of U18666a (5 μg/ml for 24 h) from
Biomol (Plymouth Meeting, PA) on RhoA activation was determined using the
G-LISA RhoA activation assay from Cytoskeleton (Denver, CO). Manufac-
turer’s protocols were followed.
2.3. Western immunoblotting
Antibodies against p21/waf1 (mouse) and cyclin D (mouse) were obtained
from Santa Cruz biotechnologies (Santa Cruz, CA). Antibody against actin
(rabbit) was obtained from Sigma-Alrich (St. Louis, MO). Protein samples were
prepared by homogenizing 60 mm dishes of cultured cells in ice cold lysis
buffer (50 mM Tris, pH 7.5, 1% Triton X-100, 100 mM NaCl, 50 mM NaF,
200 μM Na2VO4, and 10 μg/ml pepstatin and leupeptin) for 30 min at 4 °C
while shaking. Cell lysates were microcentrifuged at 4 °C at 14,000 rpm for
10 min. Proteins were separated using SDS-PAGE containing 20 to 40 μg of
protein of 6–12% acrylamide gel. The samples were transferred to an
Immobilon-P membrane (Millipore, Bedford, MA) at 15 V for 30 min. The
blots were blocked overnight in phosphate buffered saline (PBS: 138 mM
NaCl, 15 mM Na2HPO4, 1.5 mM KCl, and 2.5 mM KH2PO4) containing 10%
nonfat dehydrated milk and 0.1% Tween-20 at 4 °C. Blots were incubated
overnight with primary antibodies (both at 1:1000 dilution) in PBS containing
10% nonfat dehydrated milk and 0.1% Tween-20. Blots were washed three
times in PBS and incubated in secondary antibody conjugated to horseradish
peroxidase for 1 h at room temperature (dilution 1: 4000, Sigma). Blots were
washed again in PBS before visualizing using Super Signal chemiluminescent
substrate (Pierce, Rockford, IL) and exposing the membrane to Kodak scientific
imaging film (Kodak, Rochester, NY). Quantification of protein expression was
accomplished by densitometry software on the VersaDoc (Quality One, BioRad,
Hercules, CA).
2.4. Immunostaining
Briefly, cells were grown 55–60% confluency on Fisherbrand coverslips.
Cells were rinsed three times with phosphate buffered saline (PBS) and then
fixed with 2% paraformaldehyde for approximately 30 min. Cells were rinsed
once more with PBS and then permeabilized in 0.1% NP-40 (Sigma-Aldrich, St.
Louis, MO) in PBS for 30 min at room temperature. Cells are washed 3× in PBS
and blocked with 10% goat serum in PBS for 30 min at room temperature. Cells
are then incubated with anti-cyclin D (1:100) from Santa Cruz biotechnologies
(Santa Cruz, CA) in 10% goat serum in PBS for 1 h at room temperature. After
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mouse IgG at 10 μg/ml in 10% goat serum in PBS for 1 h at room temperature in
the dark. Results were visualized in the ultraviolet range using wide field
microscope on a Zeiss Axiovert 200 and Metamorph software. A 40× oil
objective with a GFP filter was used for all images.
2.5. Proliferation studies
Cells were treated with mevastatin (50 μM) with or without geranylger-
anylpryophosphate (GGPP) and farnesyl pyrophosphate (FPP) (Sigma-Alrich
(St. Louis, MO)) at 10 μM for 72 h. Cell permeable C3 transferase (C3) was
obtained from Cytoskeleton (Denver, CO). Cells were treated with C3 (0.5 ng/
ml) for 24 h. Cells were plated in 96 well plates (3000 cells/well) in 100 μL 0.5%
serum and growth-factor free media for 24 h prior to treatment. Proliferation was
assayed by CellTiter 96 AQueous One Solution Cell Proliferation Assay
purchased from Promega (Madison, WI) and used per manufacturer’s
instructions. After treatment, 20 μL CellTiter 96 AQueous One Solution Reagent
was added to each well in a sterile fashion and the plates were incubated for 2 h
at 37C/5% CO2. Absorbance was read at 490 nm using a 96 well plate reader.
The MTS tetrazolium salt in the reagent is bioreduced into a colored formazan
product that is proportional to the number of living cells in culture. Results are
expressed as percent absorbance at 490 nm of untreated controls. Groups are
compared using ANOVAwith the Duncan’s multiple range test.3. Results
3.1. Small GTPase activation
Previous work has demonstrated that NPC cells and CF cells
exhibit similar alteration in signaling protein profiles [2]. It has
also been established that the small GTPase RhoA exhibits
elevated activation in CF cells and tissues [4]. The hypothesisFig. 2. RhoA-GTP and Ras-GTP content in NPC and wt fibroblasts. (A) Representati
content. Data are normalized to total RhoA protein (RhoA-GTP/total RhoA). Resul
significance is determined by t-test; *p=0.006. (C) Representative gel of Ras-GT
normalized to total Ras protein (Ras-GTP/total Ras). Results are obtained from three r
t-test; *p=0.05.being tested is that the cholesterol accumulation characteristic
of NPC leads to elevated basal GTPase activation leading to
altered cell signaling regulation. To test this hypothesis, the
basal activation state of RhoA was examined in wt and NPC
human fibroblasts. The GTP-bound form of RhoA GTPase was
determined by rhotekin pull-down assay and the relative content
of RhoA-GTP was normalized to total RhoA content. RhoA
exhibits increased GTP binding in NPC fibroblasts compared to
wt fibroblasts indicating a basal increase in RhoA GTPase
signaling as a result of lost NPC1 function (Fig. 2A, B).
In order to determine if the elevated basal active state of the
small GTPases is specific for RhoA in NPC fibroblasts, the
GTP-bound form of Ras GTPase was also examined. Consistent
with RhoA activation, Ras GTP-bound content is also elevated
in NPC fibroblasts compared to wt controls (Fig. 2C, D). These
data demonstrate that NPC-related alterations in small GTPase
regulation is not specific for simply RhoA and impact both
farnesyl- (Ras) and geranylgeranyl-modified (RhoA) GTPase.
These data also suggest that RhoA and Ras GTPases are strong
candidates for effectors of NPC-related signaling alterations.
3.2. Regulation of GTPase regulated proteins
A basal increase in small GTPase signaling is predicted to
result in alterations in GTPase-dependent protein regulation.
The goal of these studies is to examine a signaling pathway
established to be influenced by small GTPases as a measure of
functional influence of increased basal GTP-bound content of
both Ras and RhoA in NPC fibroblasts. The pathway examinedve gel of RhoA-GTP pull-down assay. (B) Densitometry analysis of RhoA-GTP
ts are obtained from three replicate experiments. Error bars represent SEM and
P pull-down assay. (D) Densitometry analysis of Ras-GTP content. Data are
eplicate experiments. Error bars represent SEM and significance is determined by
Fig. 3. Protein expression of p21/waf1 in NPC and wt fibroblasts. (A)
Representative gel showing reduced p21/waf1 expression in NPC cells. Actin is
shown as a protein loading control. (B) Densitometry analysis of p21/waf1
expression normalized to actin expression (p21/actin). Results are obtained from
three replicate experiments. Error bars represent SEM and significance is
determined by t-test; *p<0.001.
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elevated Ras and RhoA signaling in breast cancer cells
resulted in reduced p21/waf1 and elevated cyclin D protein
expression. These signaling parameters were examined in NPC
fibroblasts to test whether they would exhibit changes
consistent with elevated GTPase activation. Consistent with
the hypothesis, the cyclin kinase inhibitor p21/waf1 exhibits
decreased expression in NPC fibroblasts compared to wt con-
trols (Fig. 3A–B).
Correspondingly, cyclin D content is greater in NPC
fibroblasts compared to wt controls (Fig. 4A–B). To further
assess cyclin D expression, wt and NPC fibroblasts wereFig. 4. Cyclin D expression and localization in wt and NPC fibroblasts. (A) Represent
protein loading control. (B) Densitometry analysis of cyclin D expression normalize
experiments. Error bars represent SEM and significance is determined by t-test; *p=0
fibroblasts, (D) wt fibroblasts, and (E) NPC fibroblasts with secondary antibody onimmunostained for cyclin D content. As shown in Fig. 4C–E,
NPC fibroblasts exhibit increased cyclin D content than wt
controls. Both cell types are cultured, proliferating cells. It is
expected that cyclin D, a cell cycle regulator, will be localized to
the nucleus in both cell types. However, overall content of
cyclin D in NPC cells is elevated. The above data demonstrate
that cell signaling alterations associated with elevated Ras and
RhoA GTPase activation are present in NPC fibroblasts.
The above data describe alterations in GTPase activation in
NPC cells and changes in p21/waf1 and cyclin D that are
consistent with increased GTPase signaling. In order to
determine if cholesterol accumulation characteristic of NPC is
the mechanistic source of these signaling changes, wt fibroblasts
were treated with U18666a (5 μg/ml) to induce cholesterol
accumulation and then examined for RhoA activation and cyclin
D expression. U18666a (3-beta-[2-(diethylamino)ethoxy]
androst-5-en-17-one) is a class 2 amphiphile know to inhibit
intracellular cholesterol transport and lead to NPC-like free
cholesterol accumulation [16]. RhoA activation measured by
immunodetection of GTP-bound RhoA content is elevated
(Fig. 5A) and cyclin D expression is increased (Fig. 5B, C) by
U18666a exposure. RhoA-GTP content increases approxi-
mately 10% after 24 h treatment (p=0.01). The measurement
of transient GTP binding by RhoA is the best current approach to
measure RhoA activation. However, this increase likely does not
represent a completely quantitative measure of RhoA activation,
only a qualitative trend towards increased activation. An
indirect, although more stable, measure of RhoA signaling is
the expression of cyclin D. Cyclin D expression increases by
approximately 80% (p=0.002) after U18666a treatment. Theseative gel showing elevated cyclin D expression in NPC cells. Actin is shown as a
d to actin expression (cyclin D/actin). Results are obtained from four replicate
.05. Immunostain data shown are representative images of cyclin D in (C) NPC
ly. Images are representative of three separate experiments.
Fig. 5. Effect of U18666a treatment on RhoA activation and cyclin D expression.
(A) RhoA activation in wt fibroblasts treated with U18666a (U18; 5 μg/ml) for
24 h as measured by immunodetection of GTP-bound RhoA content. Error bars
represent SEM and significance is determined by t-test; *p=0.03; n=8 for
untreated and n=14 for U18 treated cells over three experiments. (B)
Representative gel demonstrating increased cyclin D expression in response to
U18 (5μg/ml) treatment. (C) CyclinD protein expression inwt fibroblasts treated
with U18 (5 μg/ml) for 24 h as measured by Western blot. Error bars represent
SEM and significance is determined by t-test; *p=0.03; n=8 for untreated and
n=10 for U18 treated cells over three experiments.
Fig. 6. RhoA-dependent cell survival in NPC fibroblasts. (A) Data demonstrate
that FPP (10 μM) partially reverses and GGPP (10 μM) completely reverses
cytotoxicity in NPC fibroblasts induced by treatment with the HMG-CoA
reductase inhibitor mevastatin (50 μM). Results are representative of three
separate experiments with ten replicates per experiment. Error bars represent
SEM and significance is determined by ANOVA with the Duncan's multiple
range correction; **p<0.001 and *p<0.01 compared to untreated samples. (B)
The influence of the RhoA specific inhibitor (C3; 0.5 ng/ml) on cell survival in
wt (open bars) and NPC (black bars) fibroblasts. Results are representative of
five separate experiments with three to five replicates per experiment. Error bars
represent SEM and significance is determined by t-test; *p=0.003 compared to
untreated samples.
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mechanistic trigger for these cell-signaling alterations.
3.3. Proliferation
The signaling profile of elevated active GTPase content,
reduced p21/waf1 and elevated cyclin D content would be
predicted to favor proliferation and cell survival pathways of
NPC fibroblasts compared to wt controls. One potential
mechanism for this result is that altered cell signaling skews
the regulation of cell survival through the GTPase-dependent
pathway. Previous work has demonstrated that NPC cells are
sensitive to cell death caused by inhibitors of cholesterol
synthesis [12,13]. Inhibitors of cholesterol synthesis also
prevent the production of the isoprenoids farnesyl- (FPP) andgeranylgeranyl pyrophospate (GGPP). Ras and RhoA are
covalently modified by the addition of FPP and GGPP,
respectively, allowing the GTPases to be properly localized
and activated. Thus, cholesterol synthesis inhibitors effectively
reduce small GTPase function [17]. We hypothesized that NPC
sensitivity to cholesterol synthesis inhibition is due to elevated
Ras and RhoA signaling and should be reversible with the
addition of either FPP or GGPP as a means to specifically
modulate Ras and RhoA signaling. Treatment of NPC
fibroblasts with mevastatin, an inhibitor of HMG-CoA reduc-
tase, leads to cell death as previously described. However, the
addition of GGPP completely rescues mevastatin sensitivity and
FPP partially rescues NPC cells (Fig. 6A). These data support
the suggestion that NPC survival control is skewed towards
dependence on RhoA signaling.
To more directly confirm these results, the influence of the
RhoA inhibitor C3 (0.5 ng/ml, 24 h) on wt and NPC fibroblast
survival was examined. C3 exposure resulted in only 4.9±4.5%
(not significant) cell death in wt fibroblasts. However, C3 treat-
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(p=0.003) (Fig. 6B). These data demonstrate a NPC sensitivity
towards RhoA inhibition and further support an intrinsic
alteration of RhoA signaling in NPC.
4. Discussion
The above data demonstrate that NPC fibroblasts exhibit a
basal increase in the GTP-bound active form of both Ras and
RhoA small GTPases compared to wt fibroblasts. However, an
elevation of GTP-bound Ras and RhoA does not necessarily
lead to an increase in cellular responses dependent on these
pathways. To test whether signaling responses influenced by
small GTPase function are impacted in NPC fibroblasts, p21/
waf1 and cyclin D expression were examined. Based on the
work by Liberto et al., an increase in both Ras and RhoA
signaling should lead to a decrease in p21/waf1 content and an
increase in cyclin D protein expression [11]. NPC fibroblasts
exhibit this same profile in p21/waf1 and cyclin D expression
supporting the hypothesis that Ras and RhoA signaling is
functionally elevated in the absence of NPC1 function. Previous
work had demonstrated that NPC cells are sensitive to statin-
induced cell death; and this manuscript demonstrates the
reversibility of this sensitivity with the addition of GGPP, a
RhoA modifying isoprenoid. More specifically, data demon-
strate increased NPC sensitivity to RhoA inhibition compared to
wt fibroblasts further supporting the hypothesis that RhoA
signaling is basally increased in NPC.
Although these pathways need to be examined in neuronal
cell models of NPC, alterations in the regulation of cell survival
in relation to lost NPC1 function potentially impacts the poorly
defined process of neurological decline in NPC disease. One
model of neurodegeneration in Alzheimer’s suggests that
improper entry into a cell division cycle leads to neuronal cell
death [18]. Several reports have now identified an increase in
cellular proliferation markers, including cyclin D, as a precursor
to neuronal degeneration in Alzheimer’s [19–22]. The skewing
of cell survival regulation towards dependence on the RhoA
signaling pathway in NPC cells may facilitate the improper
entry into cell division leading to neurological decline.
Support for such a process being involved in NPC
neurological pathology is demonstrated in the work by Zhang
et al. [23]. Zhang et al. demonstrate the mice lacking NPC1
expression exhibit increased activation of cdk5, cdk2, and cdk4.
Treatment of NPC mice with two cdk inhibitors, roscovitine and
olomoucine, demonstrated efficacy in modulating neurological
symptoms. Among the benefits of cdk treatment were reduced
tau phosphorylation, modulation of Purkinje cell death, and
improved motor function [23]. These findings are consistent
with data from multiple Alzheimer’s studies implicating cdk
signaling, particularly cdk5, in the pathogenesis of neurological
decline [24–30]. However, recent work by Hallows et al.
provides evidence against the role of cdk5 in the pathogenesis in
NPC by ablating the expression of the cdk5 activator p35 [31].
The lack of cdk5 involvement and the efficacy of roscovitine
and olomoucine in modulating NPC neurological phenotypes
points to the involvement of cdk2 [31]. A manuscript by Guoet al. demonstrates directly the ability of RhoA to regulate the
activation of cdk2, supporting the suggestion that small GTPase
signaling is potentially involved in NPC pathogenesis [32].
This manuscript demonstrates that NPC fibroblasts exhibit an
inherent increase in small GTPase activation and that this
signaling pathway impacts how cell survival is regulated. These
data explain previous observations of NPC cell sensitivity to
cholesterol synthesis inhibition and point to a potential signaling
source of pathogenesis in NPC. In addition to the regulation of
cell growth as described above, other NPC phenotypes that are
influenced by either RhoA or Ras mediated signaling include
PPARγ activation [10] and the control of neurite outgrowth
[33,34]. Elevated signaling through small GTPases may
represent a branch point that links several phenotypic manifesta-
tions of lost NPC1 function.
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